Page last updated: 2024-12-05

allylisopropylacetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Allylisopropylacetamide: An allylic compound that acts as a suicide inactivator of CYTOCHROME P450 by covalently binding to its heme moiety or surrounding protein. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9297
SCHEMBL ID3322985
MeSH IDM0000754

Synonyms (18)

Synonym
ai3-61022
4-pentenamide, 2-(1-methylethyl)-
allylisopropylacetamide
299-78-5
2-propan-2-ylpent-4-enamide
2-isopropylpent-4-enamide
2-isopropyl-4-pentenamide
AKOS006278029
unii-zof4719qs5
zof4719qs5 ,
4-pentenamide,2-(1-methylethyl)-
SCHEMBL3322985
2-allyl-2-isopropylacetamide
W18852
Q27295821
2-(propan-2-yl)pent-4-enimidic acid
DTXSID20952350
WS-01610

Research Excerpts

Overview

Allylisopropylacetamide is shown to be a suicide substrate for the phenobarbital-inducible cytochromes P-450.

ExcerptReferenceRelevance
"Allylisopropylacetamide is shown to be a suicide substrate for the phenobarbital-inducible cytochromes P-450. "( Determination of partition ratios for allylisopropylacetamide during suicidal processing by a phenobarbital-induced cytochrome P-450 isozyme from rat liver.
Loosemore, MJ; Walsh, C; Wogan, GN, 1981
)
1.98

Pharmacokinetics

ExcerptReferenceRelevance
" MPD, the least-branched compound had the largest clearance and shortest half-life of all the amides investigated and was the least active."( Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.
Bialer, M; Haj-Yehia, A, 1989
)
0.28
"Following intravenous administration to dogs of the individual enantiomers, (R)-PID had significantly lower clearance and longer half-life than (S)-PID, however, the volumes of distribution were similar."( Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
Bennett, GD; Bialer, M; Finnell, RH; Levy, RH; Roeder, M; Schurig, V; Spiegelstein, O; Yagen, B, 1999
)
0.3
"(R)-PID demonstrated better anticonvulsant activity, lower clearance and a longer half-life compared to (S)-PID."( Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
Bennett, GD; Bialer, M; Finnell, RH; Levy, RH; Roeder, M; Schurig, V; Spiegelstein, O; Yagen, B, 1999
)
0.3
" administration of individual enantiomers to mice, with (R)-PID having lower clearance and longer half-life than (S)-PID."( Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.
Bennett, GD; Bialer, M; Blotnik, S; Finnell, RH; Isoherranen, N; Spiegelstein, O; White, HS; Wilcox, KS; Woodhead, JH; Yagen, B, 2003
)
0.32
" administration of the individual enantiomers, (S)-PID had lower clearance (CL) and volume of distribution (V) and a shorter half-life (t(1/2)) than (R)-PID."( Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide.
Bialer, M; Devor, M; Kaufmann, D; Minert, A; Tal, M; Yagen, B, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Dose-response effects for the induction of total cytochrome P450 ethoxyresorufin-O-deethylase (EROD) activity, and benzphetamine demethylase (BPDM) activity were studied using 10 selected tetra- to hexachlorinated PCB congeners."( Effects of polychlorinated biphenyls on cytochrome P450 induction in the chick embryo hepatocyte culture.
Robertson, LW; Rodman, LE; Shedlofsky, SI; Swim, AT, 1989
)
0.28
"We have determined the dose-response curves (100-900 mg of Fe/kg body wt."( Iron and the liver. Acute and long-term effects of iron-loading on hepatic haem metabolism.
Bonkowsky, HL; Healey, JF; Pomeroy, JS; Sinclair, JF; Sinclair, PR, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (277)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990240 (86.64)18.7374
1990's27 (9.75)18.2507
2000's8 (2.89)29.6817
2010's2 (0.72)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.25 (24.57)
Research Supply Index5.65 (2.92)
Research Growth Index3.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (3.19%)6.00%
Case Studies1 (0.35%)4.05%
Observational0 (0.00%)0.25%
Other272 (96.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]